Valeant aspires to #1 in derma as it adds J&J's Ortho unit for $345 million
This article was originally published in Scrip
Executive Summary
Specialty pharma Valeant Pharmaceuticals has said it will acquire the assets of the Ortho Dermatologics division of Janssen (Johnson & Johnson) for $345 million - all part of an ambitious plan on the part of the Canadian company.